Effect of magnesium trisilicate and kaolin-pectin on the bioavailability of trimethoprim.
Variability in the bioavailability of orally administered trimethoprim due to Magnesium trisilicate and Kaolin-pectin has been investigated. The concentration of trimethoprim in blood was determined spectrofluorometrically at 0, 15 and 30 minutes and 1, 2, 4 and 6 hours. The area under the blood concentration curve of trimothoprim was significantly decreased, when the drug was given concurrently with magnesium trisilicate or kaolin-pectin. The mean decrease in maximum blood concentration of trimethoprim in magnesium trisilicate and kaolin-pectin treated groups was 49.94% and 29.42% respectively. The data suggest that a clinically significant interaction may occur due to concurrent administration of trimethoprim with these drugs.
D000818:Animals; D000863:Antacids / Q000494:pharmacology*; D001682:Biological Availability; D004347:Drug Interactions; D005260:Female; D007616:Kaolin / Q000494:pharmacology*; D008274:Magnesium / Q000494:pharmacology*; D017633:Magnesium Silicates; D008297:Male; D010368:Pectins / Q000494:pharmacology*; D051381:Rats; D012824:Silicic Acid / Q000494:pharmacology*; D012822:Silicon Dioxide / Q000494:pharmacology*; D014295:Trimethoprim / Q000097:blood / Q000378:metabolism*
D000863:Antacids; D017633:Magnesium Silicates; D012824:Silicic Acid; D007616:Kaolin; D012822:Silicon Dioxide; D010368:Pectins; D014295:Trimethoprim; C001671:magnesium trisilicate; D008274:Magnesium